Equity (Details) - Schedule of Warrant Activity - Warrant [Member] - USD ($) |
9 Months Ended | |
|---|---|---|
Jan. 01, 2024 |
Sep. 30, 2024 |
|
| Schedule of Warrant Activity [Line Items] | ||
| Number of Shares Outstanding, Ending balance | 1,442 | 9 |
| Weighted Average Exercise Price Outstanding, Ending balance | $ 16.42 | $ 61.46 |
| Weighted Average Remaining Contractual Term (in years) Outstanding Ending balance | 4 months 2 days | 3 years 5 months 23 days |
| Aggregate Intrinsic Value Outstanding, Ending balance | ||
| Number of Shares, Exercisable | 9 | |
| Weighted Average Exercise Price, Exercisable | $ 65.52 | |
| Weighted Average Remaining Contractual Term (in years) Outstanding balance | 3 years 1 month 2 days | |
| Aggregate Intrinsic Value, Exercisable | ||
| Number of Shares, Granted | ||
| Weighted Average Exercise Price, Granted | ||
| Number of Warrants, Expired | (1,433) | |
| Weighted Average Exercise Price, Expired | $ 16.13 |
| X | ||||||||||
- Definition The number of share-based compensation arrangement by share-based payment award, non-options exercisable. No definition available.
|
| X | ||||||||||
- Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of non options outstanding and currently exercisable. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for vested portions of non options outstanding. No definition available.
|
| X | ||||||||||
- Definition Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on non options exercised (or share units converted) into shares. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology. No definition available.
|
| X | ||||||||||
- Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of non options outstanding. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for portions of non options outstanding. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of non-options granted during the reporting period as calculated by applying the disclosed non option pricing methodology. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of non options granted during the reporting period as calculated by applying the disclosed non option pricing methodology. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|